June 18, 2020

Phapros Collaborates with UNAIR to Produce The First Stem Cell Based Anti-Aging Serum in Indonesia

Jakarta, 18th of June 2020 - PT Phapros, Tbk, subsidiary of PT Kimia Farma Tbk, has been actively expanding its business in recent times. One of the product portfolios currently being developed is bio-based beauty products or stem-cell metabolite secretions alongside Airlangga University (UNAIR), Surabaya.

President Director of PT Phapros Tbk, Barokah Sri Utami (Emmy) commented that there is a big opportunity in the cosmetics market that needs to be fulfilled. Therefore, PT Phapros Tbk or PEHA collaborated with UNAIR’s very own stem-cell development and research center to develop non-chemical anti-aging serum.

“ This will be one of our supports to optimize downstream research. We have also received research funding from the Ministry of Research and Technology (Kemenristekdikti) in the amount of Rp. 20,2 billion since 2017. Thus, we sincerely hope that in the second half of the year, the product is ready to be produced” Emmy remarked.

Emmy explained that the product is meant to be used by the middle and upper classes as the target consumers of the first biologically based beauty serum in Indonesia. “This is because the process is quite complicated, the research itself requires a large amount of time, and it uses cells from a human body, so we come up with an estimated price of Rp. 1 million per bottle. We are also planning to collaborate with beauty clinics so that the product can be commercialized”, she added.

The 66-year-old company booked the revenue from selling the products which is still under Rp. 3 billion, but in the near future, Phapros is in high hopes that the amount will increase along with the current trends in beauty products.

The serum is still produced manually by Airlangga University, Surabaya. So, the target for sales is not set as high as other products. In the future, UNAIR plans to produce stem cell metabolite secretions as raw material for this product in a bioreactor machine that will be certified by the Indonesian Food and Drug Authority (BPOM RI), afterwards, Phapros will formulate the raw material using the production facilities of its subsidiary, PT Lucas Djaja, located in Bandung.

Previously, at the end of 2019, Airlangga University and Indonesian Food and Drug Authority (BPOM RI) had signed a Memorandum of Understanding (MoU) at the UNAIR Rectorate building related to the assistance of authorization regarding this research. The three products that are ready to be produced are stem cells, which can be used for beauty products, capsules shells from seaweed and allergens.

Rector of Airlangga University, Prof. Muhammad Nasih claimed that research products are not sufficient enough if they were just on a laboratory scale. For mass production and legality of product circulation, the support from BPOM is very much needed.

On the other hand, the Head of BPOM RI, Penny Lukito explained that the collaboration with UNAIR was in the form of partnership in accelerating the license. Specifically for clinical trial assistance because in the process of obtaining authorization, there are several products that must be clinically tested first to see some aspects such as safety, efficacy, and quality.